Loading…
Back To Schedule
Tuesday, June 16 • 11:30am - 12:30pm
#220 L: Disruptive Transformation in Safety Organizations

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Tweet Share
Component Type: Session
Level: Intermediate
CE: ACPE 1.00 Knowledge UAN: 0286-0000-20-651-L04-P; CME 1.00; IACET 1.00; RN 1.00

Pharmacovigilance (PV) transformation is top-of-mind for safety leaders. Internal and external stakeholders demand fresh thinking regarding operating models and capabilities for PV organizations. Forward-thinking leaders are pulling on multiple strategic levers, from bringing in new ways of thinking to acquiring a different type of talent to implementing game-changing technologies. The pharma companies that will be the most competitive in the future are the ones that are able to quickly transform.

Learning Objectives

Discuss how to transform their PV organizations into more strategic and elevated operating models; Describe how to adapt agile methods and approaches to the safety-critical, compliance-driven environment of healthcare;Identify how to apply the agile approach to areas other than software development.

Chair

William Gregory, PhD

Speaker

Workload! What Can We Pull Out of Our Pharmacovigilance Toolkit to Spell Success in 2030?
William Gregory, PhD

The Secret Ingredients to Reinventing Drug Safety Organizations
Kemi Yusuf, MBA, PMP

Agility and Safety: Are They Compatible?
Alan M. Hochberg


Speakers
avatar for William Gregory

William Gregory

Senior Director, Safety and Risk Management, Pfizer Inc
He received formal training in infectious diseases and molecular mechanisms of pathogenesis and has more than 15 years of experience directing global product development and registration programs. He also has extensive experience in pharmacovigilance and health informatics as well... Read More →
avatar for Kemi Yusuf

Kemi Yusuf

Head, International PV Strategy and Office of the Product Safety Team, AbbVie, Inc.
Kemi Yusuf leads International Pharmacovigilance (PV) Strategy and Office of the Product Safety Team within AbbVie. She has over 15 years of experience in developing and implementing global transformational strategies to elevate business performance, expand capabilities, strengthen... Read More →
avatar for Alan Hochberg

Alan Hochberg

Principal Scientific Enablement Director, F. Hoffmann- La Roche, Switzerland
Alan Hochberg is a Scientific Enablement Leader at Roche in Basel, involved in bringing innovations into the pharmacovigilance system. He was formerly with ProSanos, where he developed and evaluated signal-detection algorithms. He has worked in bioinformatics and biomedical engineering... Read More →

Tuesday June 16, 2020 11:30am - 12:30pm EDT
TBD Virtual Event Horsham, PA 19044
  01: ClinSafety-PV, Session